The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Effective mRNA pulmonary delivery by dry powder formulation of PEGylated synthetic KL4 peptide
Open accessAbstract
Pulmonary delivery of messenger RNA (mRNA) has considerable potential as therapy or vaccine for a range of lung diseases. Inhaled dry powder formulation of mRNA is particularly attractive as it has superior stability and dry powder inhaler is relatively easy to use. A safe and effective mRNA delivery vector as well as a suitable particle engineering method are required to produce a dry powder formulation that is respirable and mediates robust transfection in the lung. Here, we introduce a novel RNA delivery vector, PEG12KL4, in which the synthetic cationic KL4 peptide is attached to a monodisperse linear PEG of 12-mers. The PEG12KL4 formed nano-sized complexes with mRNA at 10:1 ratio (w/w) and mediated effective transfection on human lung epithelial cells. PEG12KL4/mRNA complexes were successfully formulated into dry powder by spray drying (SD) and spray freeze drying (SFD) techniques. Both SD and SFD powder exhibited satisfactory aerosol properties for inhalation. More importantly, the biological activity of the PEG12KL4 /mRNA complexes were successfully preserved after drying. Using luciferase mRNA, the intratracheal administration of the liquid or powder aerosol of PEG12KL4 /mRNA complexes at a dose of 5 μg mRNA resulted in luciferase expression in the deep lung region of mice 24 h post-transfection. The transfection efficiency was superior to naked mRNA or lipoplexes (Lipofectamine 2000), in which luciferase expression was weaker and restricted to the tracheal region only. There was no sign of inflammatory response or toxicity of the PEG12KL4 /mRNA complexes after single intratracheal administration. Overall, PEG12KL4 is an excellent mRNA transfection agent for pulmonary delivery. This is also the first study that successfully demonstrates the preparation of inhalable dry powder mRNA formulations with in vivo transfection efficiency, showing the great promise of PEG12KL4 peptide as a mRNA delivery vector candidate for clinical applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173 · cited 1×
“[2,3], but these early promising results did not immediately translate into clinic benefits due to the concerns with mRNA instability, risk of innate immunogenicity and inefficient in vivo delivery.”
BackgroundmRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues
Lai, S. K., Wang, Y.-Y., & Hanes, J. S. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.11.002 · Cited by 1,863
Polyethylene glycol (PEG): A versatile polymer for pharmaceutical applications
D’souza, A. A., & Shegokar, R. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1182485 · Cited by 1,282
Expression of therapeutic proteins after delivery of chemically modified mRNA in mice
Kormann, M. S. D., Hasenpusch, G., Aneja, M. K., Nica, G., Flemmer, A. W., Herber-Jonat, S., Huppmann, M., Mays, L. E., Illenyi, M., Schams, A., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1733 · Cited by 733
Bahl, K., Senn, J. J., Yuzhakov, O., Bulychev, A., Brito, L. A., Hassett, K. J., Laska, M. E., Smith, M., Almarsson, Ö., Thompson, J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.035 · Cited by 642
Holtkamp, S., Kreiter, S., Selmi, A., Simon, P., Koslowski, M., Huber, C., Türeci, O., & Sahin, U. (2006) · Blood · doi:10.1182/blood-2006-04-015024 · Cited by 625
PEGylation for enhancing nanoparticle diffusion in mucus
Huckaby, J. T., & Lai, S. K. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.08.010 · Cited by 484
Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems
Guan, S., & Rosenecker, J. (2017) · Gene Therapy · doi:10.1038/gt.2017.5 · Cited by 389
Inhaled Nanoformulated mRNA Polyplexes for Protein Production in Lung Epithelium
Patel, A. K., Kaczmarek, J. C., Bose, S., Kauffman, K. J., Mir, F. F., Heartlein, M. W., DeRosa, F., Langer, R., & Anderson, D. G. (2019) · Advanced Materials · doi:10.1002/adma.201805116 · Cited by 383
Protein Inhalation Powders: Spray Drying vs Spray Freeze Drying
Maa, Y., Nguyen, P., Sweeney, T. D., Shire, S. J., & Hsu, C. C. (1999) · Pharmaceutical Research · doi:10.1023/a:1018828425184 · Cited by 356
Reversal of Diabetes Insipidus in Brattleboro Rats: Intrahypothalamic Injection of Vasopressin mRNA
Jirikowski, G. F., Sanna, P. P., Maciejewski-Lenoir, D., & Bloom, F. E. (1992) · Science · doi:10.1126/science.1546298 · Cited by 282
Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis
Robinson, E., MacDonald, K. D., Slaughter, K., McKinney, M., Patel, S., Sun, C., & Sahay, G. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.014 · Cited by 272
Extracellular barriers in respiratory gene therapy
Sanders, N. N., Rudolph, C., Braeckmans, K., Smedt, S. C. D., & Demeester, J. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.09.011 · Cited by 237
mRNA as gene therapeutic: How to control protein expression
Tavernier, G., Andries, O., Demeester, J., Sanders, N. N., De Smedt, S. C., & Rejman, J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.10.020 · Cited by 232
PEGylated enhanced cell penetrating peptide nanoparticles for lung gene therapy
Osman, G., Rodriguez, J., Chan, S. Y., Chisholm, J., Duncan, G. A., Kim, N., Tatler, A. L., Shakesheff, K. M., Hanes, J. S., Suk, J. S., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.07.001 · Cited by 209
Dry powder formulations for pulmonary delivery
Malcolmson, R., & Embleton, J. K. (1998) · Pharmaceutical Science & Technology Today · doi:10.1016/s1461-5347(98)00099-6 · Cited by 177
Sebastian, M., Papachristofilou, A., Weiß, C., Früh, M., Cathomas, R. L., Hilbe, W., Wehler, T., Rippin, G., Koch, S. D., Scheel, B., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-748 · Cited by 143
Modified Foxp3 mRNA protects against asthma through an IL-10-dependent mechanism
Mays, L. E., Ammon-Treiber, S., Mothes, B., Alkhaled, M., Rottenberger, J., Müller-Hermelink, E. S., Grimm, M., Mezger, M., Beer-Hammer, S., von Stebut, E., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65351 · Cited by 113
Dry Powder Aerosol Delivery Systems: Current and Future Research Directions
Chan, H. (2006) · Journal of Aerosol Medicine · doi:10.1089/jam.2006.19.21 · Cited by 107
Recent Developments in mRNA-Based Protein Supplementation Therapy to Target Lung Diseases
Sahu, I., Haque, A. K. M. A., Weidensee, B., Weinmann, P., & Kormann, M. S. D. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.019 · Cited by 104
Screening of mRNA Chemical Modification to Maximize Protein Expression with Reduced Immunogenicity
Uchida, S., Kataoka, K., & Itaka, K. (2015) · Pharmaceutics · doi:10.3390/pharmaceutics7030137 · Cited by 90
Chemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis
Haque, A. K. M. A., Dewerth, A., Antony, J. S., Riethmüller, J., Schweizer, G. R., Weinmann, P., Latifi, N., Yasar, H., Pedemonte, N., Sondo, E., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-34960-0 · Cited by 80
Okuda, T., Morishita, M., Mizutani, K., Shibayama, A., Okazaki, M., & Okamoto, H. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.04.003 · Cited by 74
Particle Size Analysis of Aerosols from Medicinal Inhalers
Mitchell, J. P., & NAGEL, M. W. (2004) · KONA Powder and Particle Journal · doi:10.14356/kona.2004010 · Cited by 73
SERPINA1 mRNA as a Treatment for Alpha-1 Antitrypsin Deficiency
Connolly, B., Isaacs, C., Cheng, L., Asrani, K. H., & Subramanian, R. R. (2018) · Journal of Nucleic Acids · doi:10.1155/2018/8247935 · Cited by 67
Chow, M. Y. T., Qiu, Y., Lo, F. F. K., Lin, H. H. S., Chan, H., Kwok, P. C. L., & Lam, J. K. W. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.07.013 · Cited by 66
Liao, Q., Yip, L., Chow, M. Y. T., Chow, S. F., Chan, H., Kwok, P. C. L., & Lam, J. K. W. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.01.057 · Cited by 60
Liang, W., Chow, M. Y. T., Chow, S. F., Chan, H., Kwok, P. C. L., & Lam, J. K. W. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.09.045 · Cited by 56
Inhalable siRNA-loaded nano-embedded microparticles engineered using microfluidics and spray drying
Agnoletti, M., Bohr, A., Thanki, K., Wan, F., Zeng, X., Boetker, J. P., Yang, M., & Foged, C. (2017) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2017.08.001 · Cited by 53
Receptor-Interacting Protein 2 Gene Silencing Attenuates Allergic Airway Inflammation
Goh, F. Y., Cook, K. L. T. P., Upton, N. E. G., Tao, L., Lah, L. C., Leung, B. P. L., & Wong, W. S. F. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202416 · Cited by 50
Qiu, Y., Chow, M. Y. T., Liang, W., Chung, W. W. Y., Mak, J., & Lam, J. K. W. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00725 · Cited by 50
Wu, J., Wu, L., Wan, F., Rantanen, J., Cun, D., & Yang, M. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.05.019 · Cited by 47
Nebulisation of IVT mRNA Complexes for Intrapulmonary Administration
Johler, S. M., Rejman, J., Guan, S., & Rosenecker, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137504 · Cited by 46
Challenges Associated with the Pulmonary Delivery of Therapeutic Dry Powders for Preclinical Testing
Price, D. N., Kunda, N. K., & Muttil, P. (2018) · KONA Powder and Particle Journal · doi:10.14356/kona.2019008 · Cited by 44
Small interfering RNA against CD86 during allergen challenge blocks experimental allergic asthma
Asai, Y., Matsumoto, K., Fukuyama, S., Kan‐o, K., Nakano, T., Tonai, K., Ohno, T., Azuma, M., Inoue, H., & Nakanishi, Y. (2014) · Respiratory Research · doi:10.1186/s12931-014-0132-z · Cited by 39
Characterization of a New High-Dose Dry Powder Inhaler (DPI) Based on a Fluidized Bed Design
Farkas, D. R., Hindle, M., & Longest, P. W. (2015) · Annals of Biomedical Engineering · doi:10.1007/s10439-015-1335-2 · Cited by 35
Dry Powder Formulation of Plasmid DNA and siRNA for Inhalation
Chow, M., & Lam, J. K. W. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150820105916 · Cited by 34
Miwata, K., Okamoto, H., Nakashima, T., Ihara, D., Horimasu, Y., Masuda, T., Miyamoto, S., Iwamoto, H., Fujitaka, K., Hamada, H., et al. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.07.009 · Cited by 33
Monodisperse engineered PEGs for bio-related applications
Kinbara, K. (2018) · Polymer Journal · doi:10.1038/s41428-018-0074-2 · Cited by 27
Ito, T., Okuda, T., Takayama, R., & Okamoto, H. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.03.029 · Cited by 27
Flagged first, then by citations
Research works printed but not linked: 1
- Liu, 2015, Freeze-drying of proteins, Methods in molecular biology (Clifton, N.J.), 1257, 459
Cited by
Sorted by citations
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 852
mRNA vaccine: a potential therapeutic strategy
Wang, Y., Zhang, Z., Luo, J., Han, X., Wei, Y., & Wei, X. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01311-z · Cited by 422
COVID-19 mRNA vaccines: Platforms and current developments
Szabó, G. T., Mahiny, A. J., & Vlatkovic, I. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.016 · Cited by 308
Formulation and Delivery Technologies for mRNA Vaccines
Zeng, C., Zhang, C., Walker, P. G., & Dong, Y. (2020) · Current topics in microbiology and immunology · doi:10.1007/82_2020_217 · Cited by 228
Delivery Strategies for mRNA Vaccines
Ramachandran, S., Satapathy, S. R., & Dutta, T. (2022) · Pharmaceutical Medicine · doi:10.1007/s40290-021-00417-5 · Cited by 191
Metadata
- Authors
- Qiu, Y., Man, R. C. H., Liao, Q., Kung, K. L. K., Chow, M. Y. T., & Lam, J. K. W.
- Affiliations
- University of Hong Kong (HK)
- The University of Sydney (AU)
- Corresponding author
- Lam, Jenny K.W.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2019-11
- Volume
- 314
- Pages
- 102-115
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2980850909
- Cited by
- 178
- References
- 41
- Citations by year
- 2026: 11 · 2025: 28 · 2024: 25 · 2023: 37 · 2022: 36 · 2021: 24 · 2020: 15 · 2019: 1
- FWCI
- 14.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Controlled Release (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- University of Hong Kong (201711159172)
- King's College London
- National Natural Science Foundation of China (NSFC 81573373)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- mRNA delivery, pulmonary drug delivery, dry powder formulation, PEGylation, cationic peptides, spray drying, spray freeze drying, aerosol properties, intratracheal administration, luciferase expression, lipoplexes, dry powder inhaler, mRNA vaccines
- MeSH terms
- A549 Cells, Administration, Inhalation, Aerosols, Animals, Epithelial Cells, Female, Freeze Drying, Humans, Lipids, Lung, Mice, Inbred BALB C, Polyethylene Glycols, RNA, Messenger, Transfection, Intercellular Signaling Peptides and Proteins, Mice, Dry Powder Inhalers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
